iBET collaboration made public in Alloksys Press Release


Alloksys and its sister company AMRIF BV
have entered Phase I clinical human studies with its human recombinant RESCAP.
The clinical study is being carried out with TNO,
using the novel microdosing platform technology, the Centre for Human Drug
Research (CHDR) and the VU Medical Centre. This Phase I study is a first step
towards programs that gain access to the development of RESCAP as therapeutic
compound fulfilling unmet medical needs in several chronic diseases.

Development of recombinant human RESCAP was initiated by
Alloksys under the European Trans Bio program together with CEVEC Pharma (Germany) and in cooperation with
(Portugal) and Agentschap NL.

The Press
is now available.